Q2 FY2026 EarningsQ2 FY26 results beat consensus on earnings but slightly missed on profitability metrics as the company transitions from R&D to early commercialization. Revenue of $0.19M beat the $0.00M consensus due to the initial rollout of the Early Access Program and grant revenue. GAAP EPS of -$0.11 beat the -$0.14 expectation, primarily driven by disciplined R&D spending, which fell 8% YoY. However, gross margin was effectively negative due to early-stage service costs, missing the 50% technical consensus.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Nautilus Biotechnology(NAUT) the Revenue is 190 K (--%), Beat estimate;the EBIT is -15.94 M (+6.78%), Beat estimate;the EPS is -0.11 (+8.33%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.00B--
0.00B--
+0.00B--%
EBITExceed expectations
-0.02B6.78%
-0.02B12.89%
+0.00B19.67%
EPSExceed expectations
-0.118.33%
-0.1416.67%
+0.030025.00%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf